A routine shot intended to prevent shingles may offer unexpected, powerful protection for the heart. New research presented at the American College of Cardiology’s Annual Scientific Session (ACC.26) indicates that adults with existing heart disease who receive the shingles vaccine face a dramatically lower risk of heart attacks, strokes, and death within the first year of vaccination.
The findings suggest that the Shingrix or Zostavax vaccines do more than just prevent painful rashes; they may serve as a critical tool in cardiovascular prevention, particularly for high-risk populations.
The Core Findings
The study analyzed health records from 246,822 adults in the United States diagnosed with atherosclerotic heart disease—a condition characterized by plaque buildup in the arteries. Researchers compared two groups: those who received at least one dose of the shingles vaccine and those who did not. Both groups were matched for age, demographics, and other health conditions to ensure a fair comparison.
The results were striking. Within one year of vaccination, the protected group showed:
- 46% lower risk of major adverse cardiac events.
- 66% lower risk of death from any cause.
- 32% reduction in heart attack rates.
- 25% reduction in stroke rates.
- 25% reduction in heart failure incidents.
Robert Nguyen, MD, the study’s lead author and a resident physician at the University of California, Riverside, emphasized the magnitude of these benefits. He noted that the protective effect is comparable to the health gains seen from quitting smoking.
“This vaccine has been found over and over again to have cardioprotective effects for reducing heart attack, stroke and death,” Nguyen said. “Looking at the highest risk population, those with existing cardiovascular disease, these protective effects might be even greater than among the general public.”
Why Does a Shingles Shot Help the Heart?
The connection between shingles and heart health lies in the body’s inflammatory response. Shingles is caused by the reactivation of the varicella-zoster virus, which originally causes chickenpox. While most people associate shingles with painful skin rashes, the infection triggers a systemic immune response.
Previous research has shown that this inflammation can:
1. Trigger blood clots near the brain and heart.
2. Increase the risk of venous thromboembolism (blood clots in the veins).
3. Strain the cardiovascular system, leading to heart attacks or strokes.
By preventing the shingles outbreak, the vaccine indirectly prevents this inflammatory cascade, thereby reducing the likelihood of these dangerous cardiac complications.
Context and Limitations
The Centers for Disease Control and Prevention (CDC) already recommends shingles vaccination for adults aged 50 and older, as well as younger individuals with weakened immune systems. This new data reinforces that recommendation, adding cardiovascular health to the list of benefits.
However, researchers caution that the study has limitations:
– Timeframe: The analysis focused only on the first year after vaccination. While a separate 2025 study suggested benefits could last up to eight years, long-term data from this specific high-risk group is still needed.
– Lifestyle Factors: People who choose to get vaccinated may also engage in other healthy behaviors. Although the study adjusted for socioeconomic factors like education, employment, and housing, some residual influence of lifestyle choices cannot be entirely ruled out.
Despite these caveats, the large sample size and rigorous statistical methods provide strong evidence for a link between vaccination and reduced cardiovascular risk.
Conclusion
The shingles vaccine appears to be a dual-purpose shield, protecting not only against nerve pain but also against severe cardiac events in vulnerable populations. For adults over 50, especially those with heart disease, the shot offers a proven, accessible strategy to significantly lower the risk of heart attack, stroke, and death.
